In 2019 funding will be made available for 6 RIHS Junior Researcher projects. The call for these PhD grants is now open.
Criteria for application
- The first applicant is a RIHS affiliated (junior)PI or a researcher within a RIHS affiliated (junior)PI group (PI predicate per January 1, 2018).
- The work of the PhD has to be done primarily within that (j)PI group
- Only one project per (j)PI group can be submitted.
- The project should be new, not previously awarded by nor currently under review by another grant agency.
- The theme leader should confirm that the project fits and strengthens the focus of the theme
- Applicants (i.e. PI group) who received a project in the Junior researcher round 2018 are not eligible for this round.
- The project should result in a PhD graduation within Radboudumc.
Conditional on sufficient quality, relevance, feasibility and fit within a research theme, project proposals will be prioritized in the following order:
- A proposal that was evaluated externally since January 1, 2017 and received excellent reviews but was not granted (such as a VENI proposal). Attach documents such as the reviews, rebuttal and decision letter.
- A proposal that develops new methodology for the population sciences (such as a new measurement technique, a new research design or a new analysis tool).
- A proposal that creates a new collaboration with an international partner (the PhD should spend at least 6 months at the partner’s institute).
- The RIHS Grant Review Committee will assess the pre-proposals on the aspects: 1. suitability of the project for a junior researcher; 2. innovative content; 3. scientific or societal relevance.
- A maximum of 10-15 projects will be selected by the Grant Review Committee for submission of a full proposal.
- The full proposals will be assessed by the RIHS Grant Review Committee for 1. suitability of the project for a junior researcher; 2. innovative content; 3. scientific quality; 4. preliminary results; 5. scientific or societal relevance; 6. collaboration.
- An opportunity for a concise rebuttal to the review will be provided.
- The Grant Review Committee will come to an advice based on the review and the rebuttal.
- The Committee’s advice will be handed to the scientific director for prioritization and final decision.
|Submission of pre-proposals (*)||14 May 2018|
|Decision pre-proposals to applicant||6 June 2018|
|Submission of full proposals (*)||9 July 2018, 11h|
|Pre-advice to applicant||30 August 2018|
|Rebuttal by applicant (*)||10 September 2018, 11h|
|Final decision to applicant||End of September 2018|
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Evaluation of an AI system for detection of COVID-19 on Chest X-Ray images22 May 2020
In the journal Radiology RIHS researcher Keelin Murphy described how an artificial intelligence system (CAD4COVID-XRay) can identify characteristics of COVID-19 on chest x-rays with performance comparable to six independent radiologists.read more
Intra-articular corticosteroid injections increase the risk of requiring knee arthroplasty14 May 2020
In The Bone & Joint Journal, RIHS researcher Stan Wijn et al. showed that corticosteroid injections in the knee joint are associated with an increased risk of knee arthroplasty in patients with, or at risk of developing, symptomatic osteoarthritis of the knee.read more
Comenius Senior Fellowship for Jos Kole12 May 2020
Assistant professor in Healthcare Ethics, Jos Kole received a Comenius Senior Fellowship, a prestigious educational scholarship for his plan ‘Physicians with character’. Aim of this scholarship is to innovate the Master of Medicine program.read more
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)12 May 2020
In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens.read more
Early symptoms in Radboudumc healthcare workers who were tested for SARS-CoV-212 May 2020
In Eurosurveillance RIHS researcher Alma Tostmann and colleagues from the Radboudumc COVID-19 Team describe that general symptoms like fever, headache, general malaise and muscle ache were associated with a positive SARS-CoV-2 test. Respiratory symptoms however, were not predictive for SARS-CoV-2.read more
Tight controlled dose reduction of biologics in psoriasis patients7 May 2020
Published in JAMA Dermatology, RIHS researcher Selma Atalay and colleagues investigated in a randomized controlled trial a tight controlled dose reduction strategy of the biologics adalimumab, etanercept and ustekinumab in psoriasis patients.read more